辅助放疗改善早期梅克尔细胞癌患者生存:15年单中心研究
该回顾性病例系列纳入2001至2016年加州大学洛杉矶分校健康系统87例梅克尔细胞癌患者,中位生存48.0个月。单因素分析显示分期是总生存的决定因素,辅助放疗整体未显示为决定因素,但限制于早期(I和II期)时术后辅助放疗与总生存显著改善相关,Cox回归证实放疗是独立预后因素。
要点
- 早期(I和II期)梅克尔细胞癌术后辅助放疗与总生存显著改善相关。
- Cox回归显示放疗是总生存的独立预后因素,校正总体分期和切缘阴性状态后仍显著。
- 整体队列中辅助放疗未显示为总生存的决定因素。
核心结论
- 在早期梅克尔细胞癌中,术后辅助放疗可改善总生存。
- 梅克尔细胞癌侵袭性强,尤其老年患者生存预后差。
研究设计与样本
- 回顾性病例系列,回顾2001至2016年加州大学洛杉矶分校健康系统梅克尔细胞癌病例,共87例。
- 患者中男性占74%、女性占26%,诊断时平均年龄71.2岁。
主要发现
- 全部患者中位生存48.0个月。
- 全部患者2年、5年、10年总生存分别为54%、46%、26%。
- 单因素分析显示分期、T分期、N分期和M分期是总生存的显著决定因素。
- 辅助放疗整体未显示为总生存的决定因素。
- 限制于早期(I和II期)时,术后辅助放疗与总生存显著改善相关。
关键数值与推荐
- 早期梅克尔细胞癌定义为I期和II期。
- 证据等级为4。
临床怎么用
- 对早期(I和II期)梅克尔细胞癌患者,可考虑术后辅助放疗以改善总生存。
- 需前瞻性随机对照试验验证观察到的获益。
局限性
- 样本量小。
- 回顾性研究性质限制统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine neoplasm of the skin. Growing evidence supports the benefit of postoperative adjuvant radiation therapy (RT) for locoregional control, but whether it improves overall survival (OS) has been debated. Our objective was to compare the OS of MCC patients who received postoperative RT with those who received surgery alone. STUDY DESIGN: Retrospective case series. METHODS: Cases of MCC between 2001 and 2016 at the University of California, Los Angeles Health System were reviewed. We identified 87 unique cases of MCC. Among the patients, 74% were identified as male and 26% as female. The average age at diagnosis was 71.2 years. The median survival was 48.0 months. The OS of all the patients at 2 years, 5 years, and 10 years was 54%, 46%, and 26%, respectively. Univariate analysis showed that stage, T stage, N stage, and M stage were significant determinants of OS. The inclusion of RT was not found to be a determinant; however, when restricting the analysis to early-stage MCC (stages I and II), postoperative adjuvant RT was associated with significantly improved OS. A Cox regression model confirmed that inclusion of RT was an independent prognosticator of OS even when controlled for overall stage and negative margin status. The small sample size and retrospective nature of this study limit its statistical power. CONCLUSIONS: MCC is an aggressive tumor with a poor prognosis for survival especially in elderly patients. In this study, we found that RT during early-stage MCC improves OS. Prospective randomized control trials are necessary to validate the observed benefit for MCC patients. LEVEL OF EVIDENCE: 4 Laryngoscope, 1862-1866, 2018.
引用
- Han AY, Patel PB, Anderson M, et al. Adjuvant radiation therapy improves patient survival in early-stage merkel cell carcinoma: A 15-year single-institution study. Laryngoscope. 2018. PMID: 29314048. doi:10.1002/lary.27031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。